TickerFacts.

BioNexus Gene Lab Corp (BGLC): Cash & Equivalents

Annual figures by period end, from SEC filings.

$2.49M
As of 2025-12-31
$1.23M
As of 2026-06-30
-2.3%
5-year compound annual growth
$2.89M2019-12-31: $859.1K2020-12-31: $2.79M2021-12-31: $2.12M2024-12-31: $2.89M2025-12-31: $2.49M$2.49M
2019-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$2.49M-13.9%2026-04-14, Balance as of period end
2024-12-31$2.89Mn/a2026-04-14, Balance as of period end
No annual figure between 2021-12-31 and 2024-12-31.
2021-12-31$2.12M-23.8%2022-04-06, Balance as of period end
2020-12-31$2.79M+224.5%2022-04-06, Balance as of period end
2019-12-31$859.1Kn/a2021-03-30, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
BioNexus Gene Lab Corp (BGLC)2025-12-31$2.49M-13.9%
American Shared Hospital Services (AMS)2025-12-31$3.46M-68.6%
CapForce Inc. (CFOR)2025-12-31$531.3K-59.5%
Exagen Inc. (XGN)2025-12-31$32.22M+46.2%
Personalis, Inc. (PSNL)2025-12-31$124.25M+35.9%
Biodesix Inc (BDSX)2025-12-31$18.99M-27.7%
YD Bio Ltd (YDES)2025-12-31$6.01M+91.8%
GRAIL, Inc. (GRAL)2025-12-31$249.73M+16.6%
BillionToOne, Inc. (BLLN)2025-12-31$495.98M+159.0%

Compare BGLC, AMS, CFOR, XGN side by side · Screen every company in Services-Medical Laboratories ↗